Appendix 1: Syndrome-Specific Growth Charts

Size: px
Start display at page:

Download "Appendix 1: Syndrome-Specific Growth Charts"

Transcription

1 Appendix 1: Syndrome-Specific Growth Charts Figure A1.1 Height centiles for girls with untreated Turner syndrome aged 1 20 years. The gray-shaded area represents the 3rd to 97th centiles for normal girls. Pubertal staging is for normal girls. Adapted from Lyon A, Preece M, Grant D. Growth curves for girls with Turner syndrome. Arch Dis Child 1985; 60:

2 Appendix 1: Syndrome-Specific Growth Charts Figure A1.2 Height and weight centiles for boys with trisomy 21 syndrome aged 3 36 months. Adapted from Cronk C, Crocker A, Peushel S et al. Growth charts for children with Down syndrome. Pediatrics 1988; 81:

3 APPENDIX 1: SYNDROME-SPECIFIC GROWTH CHARTS Figure A1.3 Height and weight centiles for boys with trisomy 21 syndrome aged 2 18 years. The gray-shaded areas represent the comparable values for the 3rd to 97th centiles for normal children. Adapted from Cronk C, Crocker A, Peuschel S et al. Growth charts for children with Down syndrome. Pediatrics 1988; 81:

4 Appendix 1: Syndrome-Specific Growth Charts Figure A1.4 Height and weight centiles for girls with trisomy 21 syndrome aged 3 36 months. Adapted from Cronk C, Crocker A, Peuschel S et al. Growth charts for children with Down syndrome. Pediatrics 1988; 81:

5 APPENDIX 1: SYNDROME-SPECIFIC GROWTH CHARTS Figure A1.5 Height and weight centiles for girls with trisomy 21 syndrome aged 2 18 years. The gray-shaded areas represent the comparable values for the 3rd to 97th centiles for normal children. Adapted from Cronk C, Crocker A, Peuschel S et al. Growth charts for children with Down syndrome. Pediatrics 1988; 81:

6 Appendix 1: Syndrome-Specific Growth Charts Figure A1.6 Height centiles for boys with Noonan syndrome aged 0 18 years compared with normal values (dashed lines). The data were obtained from 64 Noonan syndrome males in a collaborative retrospective review. Adapted from Witt D, Keena B, Hall J et al. Growth curves for height in Noonan syndrome. Clin Genet 1986; 30: Figure A1.7 Height centiles for girls with Noonan syndrome aged 0 18 years compared with normal values (dashed lines). The data were obtained from 48 Noonan syndrome females in a collaborative retrospective review. Adapted from Witt D, Keena B, Hall J et al. Growth curves for height in Noonan syndrome. Clin Genet 1986; 30:

7 APPENDIX 1: SYNDROME-SPECIFIC GROWTH CHARTS Figure A1.8 Height centiles for boys with Silver Russell syndrome. The gray-shaded area indicates normal boys 2 standard deviations (SD). Adapted from Wollman H, Kirchner T, Enders H et al. Growth and symptoms in Silver Russell syndrome: review on the basis of 386 patients. Eur J pediatr 1995; 154: Figure A1.9 Height centiles for girls with Silver Russell syndrome. The gray-shaded area indicates normal girls 2 standard deviations (SD). Adapted from Wollman H, Kirchner T, Enders H et al. Growth and symptoms in Silver Russell syndrome: review on the basis of 386 patients. Eur J pediatr 1995; 154:

8 Appendix 1: Syndrome-Specific Growth Charts Figure A1.10 Height centiles for boys with achondroplasia (mean 2 SD) compared with normal standard curves (dashed lines). Data derived from 189 males. Adapted from Horton W, Rotter J, Rimoin D et al. Standard growth curves for achondroplasia. J Pediatr 1978; 93: Figure A1.11 Head circumference centiles for boys with achondroplasia compared with normal curves (dashed lines). Data derived from 114 males. Adapted from Horton W, Rotter J, Rimoin D et al. Standard gowth curves for achondroplasia. J Pediatr 1978; 93:

9 APPENDIX 1: SYNDROME-SPECIFIC GROWTH CHARTS Figure A1.12 Height centiles for girls with achondroplasia (mean 2 SD) compared with normal standard curves (dashed lines). Data derived from 214 females. Adapted from Horton W, Rotter J, Rimoin D et al. Standard growth curves for achondroplasia. J Pediatr 1978; 93: Figure A1.13 Head circumference centiles for girls with achondroplasia compared with normal curves (dashed lines). Data derived from 145 females. Adapted from Horton W, Rotter J, Rimoin D et al. Standard growth curves for achondroplasia. J Pediatr 1978; 93:

10 Appendix 1: Syndrome-Specific Growth Charts Figure A1.14 Linear growth in hypocondroplasic boys (solid line). Adapted from Appan S, Laurent S, Champan M et al. Growth and growth hormone therapy in hypochondroplasia. Acta paediatr Scand 1990; 79: Figure A1.15 Linear growth in hypocondroplasic girls (solid line). Adapted from Appan S, Laurent S, Champan M et al. Growth and growth hormone therapy in hypochondroplasia. Acta paediatr Scand 1990; 79:

11 APPENDIX 1: SYNDROME-SPECIFIC GROWTH CHARTS Figure A1.16 Standardized curves for height in Prader Willi syndrome (PWS) in male patients (solid line) and healthy individuals (broken line). Adapted from Butler MG, Brunschwig A, Miller LK et al. Standards for selected anthropometric measurements in Prader Willi syndrome. Pediatrics 1991; 88: Figure A1.17 Standardized curves for height in Prader Willi syndrome (PWS) in female patients (solid line) and healthy individuals (broken line). Adapted from Butler MG, Brunschwig A, Miller LK et al. Standards for selected anthropometric measurements in Prader Willi syndrome. Pediatrics 1991; 88:

12 Appendix 1: Syndrome-Specific Growth Charts Figure A1.18 Standardized curves for weight in Prader Willi syndrome (PWS) in male patients (solid line) and healthy individuals (broken line). Adapted from Butler MG, Brunschwig A, Miller LK et al. Standards for selected anthropometric measurements in Prader Willi syndrome. Pediatrics 1991; 88: Figure A1.19 Standardized curves for weight in Prader Willi syndrome (PWS) in female patients (solid line) and healthy individuals (broken line). Adapted from Butler MG, Brunschwig A, Miller LK et al. Standards for selected anthropometric measurements in Prader Willi syndrome. Pediatrics 1991; 88:

Special Needs Growth Charts

Special Needs Growth Charts Special Needs Growth Charts WIC staff are encouraged to review the online module entitled The CDC Growth Charts for Children with Special Health Care Needs. The CDC module was revised by the University

More information

APPENDIX I / Nutritional Assessment 845

APPENDIX I / Nutritional Assessment 845 APPENDIX I / Nutritional Assessment 845 Figure I-37 Weight-for-age percentile curves for girls with cerebral palsy (solid line) versus healthy individuals (broken line) ( to 12 months). (Reproduced from

More information

D own s syndrome (DS) is the most common chromosomal

D own s syndrome (DS) is the most common chromosomal 97 ORIGINAL ARTICLE Growth charts for Down s syndrome from birth to 18 years of age Å Myrelid, J Gustafsson, B Ollars, G Annerén... See end of article for authors affiliations... Correspondence to: Dr

More information

MODULE 1: Growth Assessment

MODULE 1: Growth Assessment MODULE 1: Growth Assessment LEARNING OBJECTIVES After completing this module, you will have the skills and resources to: Describe techniques to obtain accurate anthropometric data for children with special

More information

Growth hormone in children (for growth hormone deficiency, Turner's syndrome, chronic renal failure and idiopathic short stature) Anthony D, Stevens A

Growth hormone in children (for growth hormone deficiency, Turner's syndrome, chronic renal failure and idiopathic short stature) Anthony D, Stevens A Growth hormone in children (for growth hormone deficiency, Turner's syndrome, chronic renal failure and idiopathic short stature) Anthony D, Stevens A Record Status This is a critical abstract of an economic

More information

PedsCases Podcast Scripts

PedsCases Podcast Scripts PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on the Approach to Pediatric Anemia and Pallor. These podcasts are designed to give medical students an overview of key

More information

Growth hormone therapy for short stature in adolescents the experience in the University Medical Unit, National Hospital of Sri Lanka

Growth hormone therapy for short stature in adolescents the experience in the University Medical Unit, National Hospital of Sri Lanka Growth hormone therapy for short stature in adolescents Growth hormone therapy for short stature in adolescents the experience in the University Medical Unit, National Hospital of Sri Lanka K K K Gamage,

More information

CIGNA HealthCare Prior Authorization Form - Growth Hormone Medications -

CIGNA HealthCare Prior Authorization Form - Growth Hormone Medications - Pharmacy Services Phone: (800)244-6224 Fax: (800)390-9745 CIGNA HealthCare Prior Authorization Form - Growth Hormone Medications - Notice: Failure to complete this form in its entirety may result in delayed

More information

Diet in. Chris Smith Senior Paediatric Dietitian

Diet in. Chris Smith Senior Paediatric Dietitian Diet in Chris Smith Senior Paediatric Dietitian What do you recommend? How many calories does my child need? How often should I weigh my child and how do I know if the growth is good? What are the answers?

More information

HUMAN GROWTH HORMONE GENOTROPIN

HUMAN GROWTH HORMONE GENOTROPIN Drug Prior Authorization Guideline HUMAN GROWTH HORMONE GENOTROPIN (somatropin) PA9728 Covered Service: Yes when meets criteria below Prior Authorization Required: Yes Additional Information: Medicare

More information

Request for Prior Authorization Growth Hormone (Norditropin

Request for Prior Authorization Growth Hormone (Norditropin Request for Prior Authorization Growth Hormone (Norditropin, Nutropin/AQ ) Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Growth Hormone require a

More information

Janice Scott MS, RD, CSP, LD Clinical Nutrition Manager Texas Scottish Rite Hospital for Children

Janice Scott MS, RD, CSP, LD Clinical Nutrition Manager Texas Scottish Rite Hospital for Children Janice Scott MS, RD, CSP, LD Clinical Nutrition Manager Texas Scottish Rite Hospital for Children Nutrition and Disability are intimately linked. Malnutrition can directly cause or contribute to disability

More information

EVALUATION OF SHORT NECK: NEW NECK LENGTH PERCENTILES AND LINEAR CORRELATIONS WITH HEIGHT AND SITTING HEIGHT

EVALUATION OF SHORT NECK: NEW NECK LENGTH PERCENTILES AND LINEAR CORRELATIONS WITH HEIGHT AND SITTING HEIGHT EVALUATION OF SHORT NECK: NEW NECK LENGTH PERCENTILES AND LINEAR CORRELATIONS WITH HEIGHT AND SITTING HEIGHT P.V. Mahajan B.A. Bharucha ABSTRACT Qualitative impressions of neck length are often used as

More information

How to approach a child with growth concern

How to approach a child with growth concern How to approach a child with growth concern Alaa Al Nofal, MD Assistant Professor of Pediatrics Pediatric Endocrinology Sanford Children Specialty Clinic Nothing to disclose Disclosure Objectives To understand

More information

4/23/2015. Pediatric Growth Hormone Deficiency: Identification, Diagnosis, & Management. Conflict of Interest. Objectives THANK YOU!

4/23/2015. Pediatric Growth Hormone Deficiency: Identification, Diagnosis, & Management. Conflict of Interest. Objectives THANK YOU! Pediatric Growth Hormone Deficiency: Identification, Diagnosis, & Management Kent Reifschneider, MD CHKD / EVMS Norfolk, VA Conflict of Interest Speaker bureau and advisor for Pfizer Board member of The

More information

hypothyroidism Growth in early treated congenital ORIGINAL ARTICLES

hypothyroidism Growth in early treated congenital ORIGINAL ARTICLES 464 Archives of Disease in Childhood 1994; 70: 464-468 ORIGINAL ARTICLES Institute of Child Health, London D B Grant Correspondence to: Dr D B Grant, Hospital for Sick Children, Great Ormond Street, London

More information

American Journal of Medical Genetics 91: (2000)

American Journal of Medical Genetics 91: (2000) American Journal of Medical Genetics 91:298 304 (2000) Phenotypic Heterogeneity of Growth and Psychometric Intelligence in Prader-Willi Syndrome: Variable Expression of a Contiguous Gene Syndrome or Parent

More information

Prior Authorization Criteria Form This form applies to Paramount Commercial Members Only. Non-Preferred Growth Hormone Products

Prior Authorization Criteria Form This form applies to Paramount Commercial Members Only. Non-Preferred Growth Hormone Products Prior Authorization Criteria Form This form applies to Paramount Commercial Members Only Criteria: P0078 Approved: 3/2017 Reviewed: Non-Preferred Growth Hormone Products Complete/review information, sign

More information

Growth Hormone Therapy

Growth Hormone Therapy Growth Hormone Therapy Policy Number: Original Effective Date: MM.04.011 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/23/2014 Section: Prescription Drugs Place(s)

More information

GROWTH HORMONE THERAPY

GROWTH HORMONE THERAPY GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below including FDA-approved

More information

Development of disease-specific growth charts in Turner syndrome and Noonan syndrome

Development of disease-specific growth charts in Turner syndrome and Noonan syndrome Review article https://doi.org/10.6065/apem.2017.22.4.240 Ann Pediatr Endocrinol Metab 2017;22:240-246 Development of disease-specific growth charts in Turner syndrome and Noonan syndrome Tsuyoshi Isojima,

More information

Standard Growth Curves in Prader-Willi Syndrome in Japan

Standard Growth Curves in Prader-Willi Syndrome in Japan Clin Pediatr Endocrinol 1993;2 (1): 39-43 Copyright (C)1993 by The Japanese Society for Pediatric End ocrinology Standard Growth Curves in Prader-Willi Syndrome in Japan Toshiro Nagai, Yutaka Tsuchiya,

More information

GROWTH HORMONE THERAPY

GROWTH HORMONE THERAPY GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 03/01/201804/01/2019 POLICY A. INDICATIONS The indications below including

More information

GROWTH HORMONE THERAPY

GROWTH HORMONE THERAPY GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 12/30/201601/01/2018TBD03/01/2018 POLICY A. INDICATIONS The indications

More information

National Screening Committee. Child Health Sub-Group Report Growth Disorders

National Screening Committee. Child Health Sub-Group Report Growth Disorders National Screening Committee Child Health Sub-Group Report Growth Disorders September 2004 Growth Disorders The condition Growth disorders. There are many conditions that cause abnormally slow or fast

More information

Assessing Overweight in School Going Children: A Simplified Formula

Assessing Overweight in School Going Children: A Simplified Formula Journal of Applied Medical Sciences, vol. 4, no. 1, 2015, 27-35 ISSN: 2241-2328 (print version), 2241-2336 (online) Scienpress Ltd, 2015 Assessing Overweight in School Going Children: A Simplified Formula

More information

Intrauterine Growth Retardation or Small Gestational Age. Series N.14

Intrauterine Growth Retardation or Small Gestational Age. Series N.14 Intrauterine Growth Retardation or Small Gestational Age Series N.14 Patient s Guide Average Readability Leaflet Intrauterine Growth Retardation- Series 14 (Revised August 2006) This leaflet was produced

More information

TEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: HUMATROPE, NUTROPIN AQ, OMNITROPE, SAIZEN

TEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: HUMATROPE, NUTROPIN AQ, OMNITROPE, SAIZEN TEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: HUMATROPE, NUTROPIN AQ, OMNITROPE, SAIZEN STEP 1: CLEARLY PRINT AND COMPLETE TO EXPEDITE PROCESSING Date: Prescriber First & Last Name:

More information

World Health Organization Growth Standards. BC Training Module PowerPoint Speaking Notes

World Health Organization Growth Standards. BC Training Module PowerPoint Speaking Notes World Health Organization Growth Standards BC Training Module PowerPoint Speaking Notes May 30, 2011 British Columbia WHO Growth Chart Training June 2011 Page 1 PowerPoint Speaking Notes Slide 1 Title

More information

TEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: GENOTROPIN & NORDITROPIN Texas Children s Health Plan Only

TEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: GENOTROPIN & NORDITROPIN Texas Children s Health Plan Only TEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: GENOTROPIN & NORDITROPIN Texas Children s Health Plan Only STEP 1: CLEARLY PRINT AND COMPLETE TO EXPEDITE PROCESSING Date: Prescriber First

More information

3/16/2018. Normal patterns of growth Definition and causes of FTT Medical evaluation and management Effects of FTT Early intervention

3/16/2018. Normal patterns of growth Definition and causes of FTT Medical evaluation and management Effects of FTT Early intervention WI CAN Educational Series Hillary W. Petska, MD, MPH, FAAP Child Advocacy and Protection Services Children s Hospital of Wisconsin Normal patterns of growth Definition and causes of FTT Medical evaluation

More information

Growth Charts for Non-Growth Hormone Treated Prader-Willi Syndrome

Growth Charts for Non-Growth Hormone Treated Prader-Willi Syndrome Growth Charts for Non-Growth Hormone Treated Prader-Willi Syndrome Merlin G. Butler, MD, PhD a, Jaehoon Lee, PhD b, Ann M. Manzardo, PhD a, June-Anne Gold, MD c, Jennifer L. Miller, MD d, Virginia Kimonis,

More information

Endocrine: Precocious Puberty Health care guidelines for Spina Bifida

Endocrine: Precocious Puberty Health care guidelines for Spina Bifida Endocrine: Precocious Puberty Health care guidelines for Spina Bifida Precocious Puberty Primary outcome: Timely assessment, identification, appropriate referral, and management of precocious puberty.

More information

Failure to Thrive Severity Determination by New Design Curves in Standard Growth Charts

Failure to Thrive Severity Determination by New Design Curves in Standard Growth Charts Failure to Thrive Severity Determination by New Design Curves in Standard Growth Charts Firouzeh Hosseini *1, Babak Borzouei *2, and Mehrangiz Vahabian 2 1 Department of Pediatrics, Besat Hospital, Hamedan

More information

Blood pressure charts for pediatrics

Blood pressure charts for pediatrics Blood pressure charts for pediatrics Blood pressure screening is essential throughout life. Adult blood pressure assessments have static thresholds of 140/90 for hypertension and 90/60 for hypotension

More information

OZGROW Report 2009/2010

OZGROW Report 2009/2010 OZGROW Report 2009/2010 GH therapy in Australia As of May 2010 there are 1636 children receiving GH treatment in Australia under the PBS. The Department of Health and Ageing s (DoHA) indication for GH

More information

WHO Child Growth Standards

WHO Child Growth Standards WHO Child Growth Standards Implications for everyday practice Dr Mercedes de Onis Department of Nutrition World Health Organization Geneva, Switzerland 1 year 2 years 3 years 4 years 5 years WHO Child

More information

GROWTH ASSESSMENT AND GROWTH DISORDERS. IAP UG Teaching slides

GROWTH ASSESSMENT AND GROWTH DISORDERS. IAP UG Teaching slides GROWTH ASSESSMENT AND GROWTH DISORDERS 1 GROWTH PARAMETERS TO BE MONITORED Birth 2 years: Weight, length & head circumference at birth, immunization contacts at 6, 10, 14 weeks, 9 months, 15 months & 18

More information

Body Composition and Fatness Patterns in Prader-Willi Syndrome: Comparison with Simple Obesity

Body Composition and Fatness Patterns in Prader-Willi Syndrome: Comparison with Simple Obesity Original Research as Short Communication Body Composition and Fatness Patterns in Prader-Willi Syndrome: Comparison with Simple Obesity Mariana F. Theodoro, Zohreh Talebizadeh, and Merlin G. Butler Abstract

More information

Growth variations and secular trend in Argentina

Growth variations and secular trend in Argentina XIV Congreso Internacional de Auxología «Por un crecimiento saludable en un mundo mejor» CRECIMIENTO EN PAÍSES LATINOAMERICANOS: SIMILITUDES Y DIFERENCIAS Growth variations and secular trend in Argentina

More information

Somatostatin Analog and Estrogen Treatment in a Tall Girl

Somatostatin Analog and Estrogen Treatment in a Tall Girl Clin Pediatr Endocrinol 1995; 4 (2): 163-167 Copyright (C) 1995 by The Japanese Society for Pediatric Endocrinology Somatostatin Analog and Estrogen Treatment in a Tall Girl Toshiaki Tanaka, Mari Satoh,

More information

Genotropin, Norditropin, Nutropin, Nutropin AQ, Humatrope, Saizen,

Genotropin, Norditropin, Nutropin, Nutropin AQ, Humatrope, Saizen, Blue Cross Blue Shield of Vermont and The Vermont Health Plan Prior Approval Guidelines Human Growth Hormone Somatropin (Genotropin, Norditropin, Nutropin, Nutropin AQ, Humatrope, Serostim, Saizen, Zomacton/TevTropin,

More information

Aetna Better Health of Virginia

Aetna Better Health of Virginia Genotropin Nutropin Serostim Zomacton Humatrope Omnitrope Zorbtive somatropin Norditropin Saizen General Criteria for Approval: Omnitrope vial formulation is the preferred Growth Hormone product; consideration

More information

Weight, height and BMI references in Elazığ: an east Anatolian city

Weight, height and BMI references in Elazığ: an east Anatolian city The Turkish Journal of Pediatrics 2011; 53: 404-412 Original Weight, height and BMI references in Elazığ: an east Anatolian city Edibe Pirinçci 1, M Mümtaz Mazıcıoğlu 2, Ufuk Berberoğlu 3, Yasemin Açık

More information

Age-appropriate body mass index in children with achondroplasia: interpretation in relation to indexes of height 1 3

Age-appropriate body mass index in children with achondroplasia: interpretation in relation to indexes of height 1 3 Age-appropriate body mass index in children with achondroplasia: interpretation in relation to indexes of height 1 3 Julie E Hoover-Fong, Kerry J Schulze, John McGready, Hillary Barnes, and Charles I Scott

More information

This CNE activity is supported by an educational grant from Novo Nordisk Inc.

This CNE activity is supported by an educational grant from Novo Nordisk Inc. This CNE activity is supported by an educational grant from Novo Nordisk Inc. Objectives Differentiate between normal growth variants and growth variants that are linked to a disorder Describe the process

More information

Growth Charts for Children With Down Syndrome in the United States

Growth Charts for Children With Down Syndrome in the United States Growth Charts for Children With Down Syndrome in the United States Babette S. Zemel, PhD a,b, Mary Pipan, MD b,c, Virginia A. Stallings, MD a,b, Waynitra Hall, MS a, Kim Schadt, MSN b,c, David S. Freedman,

More information

AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents

AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents Aetna Better Health 2000 Market Street, Suite 850 Philadelphia, PA 19103 AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents Revised April 2014 Growth

More information

Committee Approval Date: January 19, 2015 Next Review Date: January 2016

Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Medication Policy Manual Policy No: dru126 Topic: Increlex, mecasermin Date of Origin: January 3, 2006 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: February

More information

The science behind igro

The science behind igro The science behind igro igro is an interactive tool that can help physicians evaluate growth outcomes in patients receiving growth hormone (GH) treatment. These pages provide an overview of the concepts

More information

Month/Year of Review: September 2013 Date of Last Review: September 2012

Month/Year of Review: September 2013 Date of Last Review: September 2012 Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights

More information

SCRIPT: Module 3. Interpreting the WHO Growth Charts for Canada SLIDE NUMBER SLIDE SCRIPT

SCRIPT: Module 3. Interpreting the WHO Growth Charts for Canada SLIDE NUMBER SLIDE SCRIPT SCRIPT: Module 3 Interpreting the WHO Growth Charts for Canada 1 Welcome Welcome to Module 3 - Interpreting the WHO Growth Charts for Canada. Each of the modules in this training package has been designed

More information

and LHRH Analog Treatment in

and LHRH Analog Treatment in Endocrine Journal 1996, 43 (Suppl), S13-S17 Combined GH Short Children and LHRH Analog Treatment in TosHIAKI TANAKA***, MARL SATOH**, AND ITSURo HIBI* *Division of Endocrinology & Metabolism, National

More information

PFIZER INC. PROTOCOL TITLE: Efficacy and Safety of the Authentic Recombinant Human Somatropin Genotropin in Children with Familial Short Stature

PFIZER INC. PROTOCOL TITLE: Efficacy and Safety of the Authentic Recombinant Human Somatropin Genotropin in Children with Familial Short Stature PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

Paula van Dommelen. Evidence-based referral criteria in growth monitoring

Paula van Dommelen. Evidence-based referral criteria in growth monitoring Paula van Dommelen Evidence-based referral criteria in growth monitoring Evidence-based referral criteria in growth monitoring Paula van Dommelen Evidence-based referral criteria in growth monitoring ISBN

More information

I n the diagnostic work-up of children with exceptionally

I n the diagnostic work-up of children with exceptionally 87 ORIGINAL ARTICLE Nationwide age references for sitting height, leg length, and sitting height/height ratio, and their diagnostic value for disproportionate growth disorders A M Fredriks, S van Buuren,

More information

GH therapy in PWS (& other endocrine problems) Dr. Shankar Kanumakala Consultant Paediatrician Brighton, UK

GH therapy in PWS (& other endocrine problems) Dr. Shankar Kanumakala Consultant Paediatrician Brighton, UK GH therapy in PWS (& other endocrine problems) Dr. Shankar Kanumakala Consultant Paediatrician Brighton, UK Overview GH therapy Indications Specific advantages Extra precautions Case scenarios without

More information

Distribution of T4 TSH Values in Children - the Shifa Experience

Distribution of T4 TSH Values in Children - the Shifa Experience Distribution of T4 TSH Values in Children - the Shifa Experience Y. Najam,M. Khan ( Departments of Pediatrics, Shifa International Hospital, Islamabad. ) F. Ilahi,A. Alam ( Departments of Biochemistry,

More information

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES Generic Brand HICL GCN Exception/Other SOMATROPIN HUMATROPE GENOTROPIN NORDITROPIN NORDITROPIN FLEXPRO NORDITROPIN NORDIFLEX NUTROPIN NUTROPIN AQ OMNITROPE SAIZEN ZOMACTON 02824 BRAND ZORBTIVE BRAND SEROSTIM

More information

Evidence-based referral criteria in growth monitoring

Evidence-based referral criteria in growth monitoring Evidence-based referral criteria in growth monitoring Paula van Dommelen Evidence-based referral criteria in growth monitoring Evidence-based verwijscriteria voor groei (met een samenvatting in het Nederlands)

More information

A total of 3061 children, 1528 boys and 1533 girls. aged 4-19 years, were included in the analysis. Table 1. Does your child have: 1 Asthma ( ) ( )

A total of 3061 children, 1528 boys and 1533 girls. aged 4-19 years, were included in the analysis. Table 1. Does your child have: 1 Asthma ( ) ( ) Archives of Disease in Childhood, 1989, 64, 96-102 Growth and other factors flow rate affecting peak expiratory J W K CARSON,* H HOEY,*t AND M R H TAYLOR*t *National Children's Hospital and tdepartment

More information

1389 (54 )1 - *** *** *** ** *** * * ** *** ( ) : /8/26 : 88/2/1 : (WC) (BMI) :.. (CVD) - : :

1389 (54 )1 - *** *** *** ** *** * * ** *** ( ) : /8/26 : 88/2/1 : (WC) (BMI) :.. (CVD) - : : JQUMS, Vol.14, No.1, Spring 2010 18 Predicting risk factors of cardiovascular disease according to anthropometric measures in children and adolescents R Kelishadi* M Hashemipour** Z Faghihimani*** E Nazemi***

More information

Growth Hormone plus Childhood Low- Dose Estrogen in Turner s Syndrome. N Engl J Med 2011;364: Present by R5 郭恬妮

Growth Hormone plus Childhood Low- Dose Estrogen in Turner s Syndrome. N Engl J Med 2011;364: Present by R5 郭恬妮 Growth Hormone plus Childhood Low- Dose Estrogen in Turner s Syndrome N Engl J Med 2011;364:1230-42. Present by R5 郭恬妮 Introduction Turner s syndrome : partial or complete X-chromosome monosomy, 1 in 2000

More information

Diagnosing Growth Disorders. PE Clayton School of Medical Sciences, Faculty of Biology, Medicine & Health

Diagnosing Growth Disorders. PE Clayton School of Medical Sciences, Faculty of Biology, Medicine & Health Diagnosing Growth Disorders PE Clayton School of Medical Sciences, Faculty of Biology, Medicine & Health Content Normal pattern of growth and its variation Using growth charts Interpreting auxological

More information

Policies, Procedures, Guidelines and Protocols

Policies, Procedures, Guidelines and Protocols Policies, Procedures, Guidelines and Protocols Document Details Title Sleep Disordered Breathing Guideline Trust Ref No 2073-38165 Local Ref (optional) Main points the document covers Diagnosis, investigation

More information

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

PDF hosted at the Radboud Repository of the Radboud University Nijmegen PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/71147

More information

PFIZER INC. Study Centre: One centre from Hungary enrolled subjects in this study

PFIZER INC. Study Centre: One centre from Hungary enrolled subjects in this study PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

PHARMACY POLICY STATEMENT Indiana Medicaid

PHARMACY POLICY STATEMENT Indiana Medicaid DRUG NAME BILLING CODE BENEFIT TYPE SITE OF SERVICE ALLOWED COVERAGE REQUIREMENTS LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY PHARMACY POLICY STATEMENT Indiana Medicaid Norditropin (somatropin)

More information

PHARMACY POLICY STATEMENT Indiana Medicaid

PHARMACY POLICY STATEMENT Indiana Medicaid DRUG NAME BILLING CODE BENEFIT TYPE SITE OF SERVICE ALLOWED COVERAGE REQUIREMENTS LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY PHARMACY POLICY STATEMENT Indiana Medicaid Zomacton (somatropin) Must

More information

World Health Organization Growth Standards. First Nations and Inuit Health Alberta Region: Training Module May 2011

World Health Organization Growth Standards. First Nations and Inuit Health Alberta Region: Training Module May 2011 World Health Organization Growth Standards First Nations and Inuit Health Alberta Region: Training Module May 2011 Acknowledgements First Nation and Inuit Health Alberta Region would like to thank the

More information

2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)? Pharmacy Prior Authorization AETA BETTER HEALTH KETUCK Growth Hormone (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and

More information

Circle Yes or No Y N. [If yes, skip to question 30.] 2. Is this request for a child? Y N. [If no, skip to question 20.]

Circle Yes or No Y N. [If yes, skip to question 30.] 2. Is this request for a child? Y N. [If no, skip to question 20.] 05/20/2015 Prior Authorization MERC CARE PLA (MEDICAID) Growth Hormone (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency London, 15 November 2007 Doc. Ref. EMEA/CHMP/EWP/517497/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON CLINICAL EVALUATION OF MEDICINAL PRODUCTS USED

More information

Growth after renal transplants

Growth after renal transplants Archives of Disease in Childhood, 1983, 58, 110-114 Growth after renal transplants M BOSQUE, A MUNIAN, M BEWICK, G HAYCOCK, AND C CHANTLER Evelina Children's Department, Guy's Hospital, London SUMMARY

More information

Growth hormone therapy in a girl with Turner syndrome showing a large increase over the initially predicted ht of 4 5

Growth hormone therapy in a girl with Turner syndrome showing a large increase over the initially predicted ht of 4 5 Disorders of Growth and Puberty: How to Recognize the Normal Variants vs Patients Who Need to be Evaluated Paul Kaplowitz, M.D Pediatric Endocrinology. VCU School of Medicine Interpretation of Growth Charts

More information

Clinical Guideline ADRENARCHE MANAGEMENT OF CHILDREN PRESENTING WITH SIGNS OF EARLY ONSET PUBIC HAIR/BODY ODOUR/ACNE

Clinical Guideline ADRENARCHE MANAGEMENT OF CHILDREN PRESENTING WITH SIGNS OF EARLY ONSET PUBIC HAIR/BODY ODOUR/ACNE Clinical Guideline ADRENARCHE MANAGEMENT OF CHILDREN PRESENTING WITH SIGNS OF EARLY ONSET PUBIC HAIR/BODY ODOUR/ACNE Includes guidance for the distinction between adrenarche, precocious puberty and other

More information

OBJECTIVES OVERVIEW 5/30/2012. IL WIC Program Risk Factor Changes July 1, 2012

OBJECTIVES OVERVIEW 5/30/2012. IL WIC Program Risk Factor Changes July 1, 2012 IL WIC Program Risk Factor Changes July 1, 2012 AUTOPLOT OBJECTIVES State the Center for Disease Control (CDC) new growth chart recommendations for birth to 24 months incorporating the WHO growth standards.

More information

Growth and metabolic consequences of growth hormone treatment in prepubertal short normal children

Growth and metabolic consequences of growth hormone treatment in prepubertal short normal children Archives of Disease in Childhood 1994; 71: 21-26 Southampton University Hospitals Trust, Tremona Road, Southampton S9 4XY, Department of Child Health E S McCaughey J Mulligan L D Voss Department of Paediatrics

More information

The Development of Reference Values for Waist Circumference, Waist Hip and Waist Height Ratios in Egyptian Adolescents.

The Development of Reference Values for Waist Circumference, Waist Hip and Waist Height Ratios in Egyptian Adolescents. Curr Pediatr Res ; (1&2): - ISSN 09-9032 www.currentpediatrics.com The Development of Reference Values for Waist Circumference, Waist Hip and Waist Height Ratios in Egyptian Adolescents. Alaa Youssef Ahmed

More information

National Child Measurement Programme Changes in children s body mass index between 2006/07 and 2010/11

National Child Measurement Programme Changes in children s body mass index between 2006/07 and 2010/11 National Child Measurement Programme Changes in children s body mass index between 2006/07 and 2010/11 Delivered by NOO on behalf of the Public Health Observatories in England Published: March 2012 NOO

More information

Body Mass Index reference curves for children aged 3 19 years from Verona, Italy

Body Mass Index reference curves for children aged 3 19 years from Verona, Italy European Journal of Clinical Nutrition (1997) 51, 6±10 ß 1997 Stockton Press All rights reserved 0954±3007/97 $12.00 Body Mass Index reference curves for children aged 3 19 years from Verona, Italy A Luciano

More information

Pubertal Development in Japanese Boys

Pubertal Development in Japanese Boys Clin Pediatr Endocrinol 1993; (SuPP13): 7-14 Copyright (C)1993 by The Japanese Society for Pediatric Endocrinology Pubertal Development in Japanese Boys Kenji Fujieda, M.D., Ph. D. Department of Pediatrics,

More information

Linear Growth Assessment: Evaluation and Causes and Treatment of Growth Failure

Linear Growth Assessment: Evaluation and Causes and Treatment of Growth Failure Linear Growth Assessment: Evaluation and Causes and Treatment of Growth Failure Terri H. Lipman PhD, CRNP, FAAN University of Pennsylvania, School of Nursing Children s Hospital of Philadelphia Growth

More information

Study of Serum Hepcidin as a Potential Mediator of the Disrupted Iron Metabolism in Obese Adolescents

Study of Serum Hepcidin as a Potential Mediator of the Disrupted Iron Metabolism in Obese Adolescents Study of Serum Hepcidin as a Potential Mediator of the Disrupted Iron Metabolism in Obese Adolescents Prof. Azza Abdel Shaheed Prof. of Child Health NRC National Research Centre Egypt Prevalence of childhood

More information

Judith Ross, 1 Peter A. Lee, 2 Robert Gut, 3 and John Germak Introduction

Judith Ross, 1 Peter A. Lee, 2 Robert Gut, 3 and John Germak Introduction Hindawi Publishing Corporation International Journal of Pediatric Endocrinology Volume 2010, Article ID 494656, 7 pages doi:10.1155/2010/494656 Research Article Factors Influencing the One- and Two-Year

More information

The Presence of Normal Levels of Serum Immunoreactive Insulin-like Growth Factor 2 (IGF-2) in Patients with Down's Syndrome

The Presence of Normal Levels of Serum Immunoreactive Insulin-like Growth Factor 2 (IGF-2) in Patients with Down's Syndrome Upsala J Med Sci 89: 274278, 1984 The Presence of Normal Levels of Serum Immunoreactive Insulin-like Growth Factor 2 (IGF-2) in Patients with Down's Syndrome Goran Annerkn,' Gosta Enberg,' and Vicki R.

More information

Growth hormone treatment in young children with Down s syndrome: evects on growth and psychomotor development

Growth hormone treatment in young children with Down s syndrome: evects on growth and psychomotor development 334 Genetics and Pathology, Unit of Clinical Genetics, Uppsala University Children s Hospital, S-751 85 Uppsala, Sweden G Annerén Paediatrics, Uppsala University Children s Hospital T Tuvemo J Gustafsson

More information

Student Guide Module 8: Nutrition and Malnutrition

Student Guide Module 8: Nutrition and Malnutrition Student Guide Module 8: Nutrition and Malnutrition Objectives of the station Plan and develop measures to assess the nutritional status of populations displaced by disasters, and to ensure optimal nutritional

More information

General Approval Criteria for ALL Growth Hormone agents: (ALL criteria must be met)

General Approval Criteria for ALL Growth Hormone agents: (ALL criteria must be met) Growth Hormone Agents Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients Page 1 of 7 Preferred Agents Somatropin Pen (Norditropin ) Somatropin Pen (Nutropin AQ ) Non-Preferred

More information

Monitoring treatment in congenital adrenal

Monitoring treatment in congenital adrenal Archives of Disease in Childhood, 1989, 64, 1235-1239 Monitoring treatment in congenital adrenal hyperplasia S APPAN, P C HINDMARSH, AND C G D BROOK Endocrine Unit, Middlesex Hospital, London SUMMARY We

More information

Ch 7 Extending Mendelian Genetics

Ch 7 Extending Mendelian Genetics Ch 7 Extending Mendelian Genetics Studying Human Genetics A pedigree is a chart for tracing genes in a family. Used to determine the chances of offspring having a certain genetic disorder. Karyotype=picture

More information

Critical Growth Phases for Adult Shortness

Critical Growth Phases for Adult Shortness American Journal of Epidemiology Copyright 2000 by The Johns Hopkins University chool of Hygiene and Public Health All rights reserved Vol. 2, o. 2 Printed in U..A. Critical Growth Phases for Adult hortness

More information

Growth promoting treatment: When discretion is the better part of value

Growth promoting treatment: When discretion is the better part of value Growth promoting treatment: When discretion is the better part of value David B. Allen, MD Professor of Pediatrics University of Wisconsin School of Medicine and Public Health Head of Division of Diabetes

More information

Expert Committee Recommendations on the Assessment, Prevention and Treatment of Child and Adolescent Overweight and Obesity

Expert Committee Recommendations on the Assessment, Prevention and Treatment of Child and Adolescent Overweight and Obesity Expert Committee Recommendations on the Assessment, and Treatment of Child and Adolescent Over and Obesity - 2007 - An Implementation Guide from the Childhood Obesity Action Network - Overview: In 2005,

More information

Effect of Growth Hormone Therapy on Adult Height of Children with Turner Syndrome

Effect of Growth Hormone Therapy on Adult Height of Children with Turner Syndrome ORIGINAL ARTICLE Effect of Growth Hormone Therapy on Adult Height of Children with Turner Syndrome Ping-Yi Hsu, Yi-Ching Tung, Wen-Yu Tsai,* Jing-Sheng Lee, Pei-Hung Hsiao Background/Purpose: Short stature

More information

GROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY CHILD AND ADOLESCENT

GROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY CHILD AND ADOLESCENT 1. Medical Condition TUEC Guidelines GROWTH HORMONE DEFICIENCY AND OTHER INDICATIONS FOR GROWTH HORMONE THERAPY CHILD AND ADOLESCENT Growth Hormone Deficiency and other indications for growth hormone therapy

More information

Growth Hormones DRUG.00009

Growth Hormones DRUG.00009 Market DC Growth Hormones DRUG.00009 Override(s) Prior Authorization Quantity Limit Approval Duration WPM PAB Center: Thirty (30) day exception for recently expired (within the past 45 days) growth hormone

More information